A Multicentre, open label, Phase I-Ib Clinical Trial Combining Melanoma-Specific Peptide Vaccination (UniCanVax) and Anti PD-1 Inhibitor (Nivolumab) in Immune Checkpoint Blockade Refractory Metastatic or Unresectable Stage III/IV Melanoma Patients

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 25
• 5 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that has spread or cannot be removed by surgery, and that no longer responds to immune checkpoint blocker treatment. It tests a melanoma peptide vaccine (UniCanVax) together with nivolumab.

Age

18 years or older

Sex

All sexes can join

Disease stage

Metastatic or unresectable stage III/IV melanoma that is refractory to immune checkpoint blockade

Earlier treatment

Previous immune checkpoint blocker treatment that no longer works (refractory)

Read by machine on 9 Nov 2026.

Sites (5)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details